CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 37 of 37 entries

View as:

A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump

Phase: N/A Priority: Normal

NCT ID: NCT00266539 Org: User:

Start: 04/30/04 End: 04/30/05 Due: 04/30/06

Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain

Phase: N/A Priority: Normal

NCT ID: NCT00410943 Org: User:

Start: - End: 06/30/99 Due: 06/30/00

A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.

Phase: N/A Priority: Normal

NCT ID: NCT00269750 Org: User:

Start: 07/31/96 End: 02/28/97 Due: 02/28/98

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Phase: N/A Priority: Normal

NCT ID: NCT00211094 Org: User:

Start: - End: 06/30/04 Due: 06/30/05

Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder

Phase: N/A Priority: Normal

NCT ID: NCT00293839 Org: User:

Start: - End: 12/31/02 Due: 12/31/03

Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System

Phase: N/A Priority: Normal

NCT ID: NCT00990418 Org: User:

Start: 03/31/08 End: 06/30/08 Due: 06/30/09

An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)

Phase: N/A Priority: Normal

NCT ID: NCT00399048 Org: User:

Start: - End: 05/31/01 Due: 05/31/02

A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence

Phase: N/A Priority: Normal

NCT ID: NCT00269724 Org: User:

Start: 03/31/97 End: 09/30/97 Due: 09/30/98

A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain

Phase: N/A Priority: Normal

NCT ID: NCT00410878 Org: User:

Start: - End: 08/31/99 Due: 08/31/00

A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.

Phase: N/A Priority: Normal

NCT ID: NCT00410540 Org: User:

Start: - End: 05/31/01 Due: 05/31/02

A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain

Phase: N/A Priority: Normal

NCT ID: NCT00398788 Org: User:

Start: - End: 11/30/01 Due: 11/30/02

Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain

Phase: N/A Priority: Normal

NCT ID: NCT00411268 Org: User:

Start: - End: 06/30/01 Due: 06/30/02

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump	NCT00266539	Alza Corporation, DE, USA	user2@example.com	None	2004-04-30	2005-04-30	2006-04-30	-	-	2025-07-14
Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain	NCT00410943	Alza Corporation, DE, USA	user2@example.com	None	-	1999-06-30	2000-06-30	-	-	2025-07-14
A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.	NCT00269750	Alza Corporation, DE, USA	user2@example.com	None	1996-07-31	1997-02-28	1998-02-28	-	-	2025-07-14
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation	NCT00211094	Alza Corporation, DE, USA	user2@example.com	None	-	2004-06-30	2005-06-30	-	-	2025-07-14
Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder	NCT00293839	Alza Corporation, DE, USA	user2@example.com	None	-	2002-12-31	2003-12-31	-	-	2025-07-14
Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System	NCT00990418	Alza Corporation, DE, USA	user2@example.com	None	2008-03-31	2008-06-30	2009-06-30	-	-	2025-07-14
An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)	NCT00399048	Alza Corporation, DE, USA	user2@example.com	None	-	2001-05-31	2002-05-31	-	-	2025-07-14
A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence	NCT00269724	Alza Corporation, DE, USA	user2@example.com	None	1997-03-31	1997-09-30	1998-09-30	-	-	2025-07-14
A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain	NCT00410878	Alza Corporation, DE, USA	user2@example.com	None	-	1999-08-31	2000-08-31	-	-	2025-07-14
A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.	NCT00410540	Alza Corporation, DE, USA	user2@example.com	None	-	2001-05-31	2002-05-31	-	-	2025-07-14
A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain	NCT00398788	Alza Corporation, DE, USA	user2@example.com	None	-	2001-11-30	2002-11-30	-	-	2025-07-14
Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain	NCT00411268	Alza Corporation, DE, USA	user2@example.com	None	-	2001-06-30	2002-06-30	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance